GU Cancers 2024 | MOVES: assessing the value of exercise in enhancing cancer prognoses

Jorma Sormunen, MD, PhD, MBA, University of Tampere, Tampere, Finland, provides an overview of the Phase III MOVES study (NCT05796973), which investigated the potential role of exercise and atorvastatin in improving patient prognosis. Patients with breast, kidney, ovarian, or prostate cancer undergoing first line treatment either receiver supervised exercise for three months, or were in a control group. The exercise will aim to create a more aerobic environment in the tumor microenvironment. The primary outcome is progression-free survival and secondary outcomes include overall survival, quality of life, hypoxia marker levels, cancer metabolites, and treatment tolerability. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.